Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

Pfizer

Status

Conditions: Alopecia Areata

Treatments: Drug: Ritlecitinib

Study type: Expanded Access

Funder types: Industry; Other

Identifiers

NCT05522556

B798

Details and patient eligibility

About

Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.

Full description

In Expanded Access, treating physicians are the Sponsors. Expanded Access requests from treating physicians may be submitted to www.pfizercares.com. Availability will depend on location and country.

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Must have ≥ 50% hair loss on scalp due to Alopecia Areata (AA) and be intolerant or have inadequate response to all commonly used AA therapies accessible in the country. Additional eligibility criteria may be required.